BeyondSpring (BYSI) Share-based Compensation (2017 - 2026)
BeyondSpring (BYSI) posted Share-based Compensation of $461000.0 for Q1 2026, up 172.78% sequentially from $169000.0 in Q4 2025, and up 88.93% YoY from $244000.0 in Q1 2025.
BeyondSpring (BYSI) Share-based Compensation (2017 - 2026) Analysis & Trends
BeyondSpring has reported Share-based Compensation for 10 years, with the latest figure at $461000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 88.93% year-over-year to $461000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $934000.0 (down 58.71% YoY) and the FY2025 annual result came in at $724000.0, down 68.08% from the prior year.
- Share-based Compensation improved to $461000.0 in Q1 2026 per BYSI's latest filing, from $169000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.1 million in Q4 2022 and troughed at $141000.0 in Q2 2025.
- A 5-year average of $458090.9 and a median of $412000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 154.08% in 2022, then slumped 81.83% in 2025.
- Over 5 years, Share-based Compensation stood at $1.1 million in 2022, then tumbled by 52.49% to $516000.0 in 2023, then fell by 20.16% to $412000.0 in 2024, then tumbled by 58.98% to $169000.0 in 2025, then surged by 172.78% to $461000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $461000.0, $169000.0, and $163000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 570,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 570,000.00 |
| Jun 30, 2026 | 570,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Dec 31, 2024 | 412,000.00 |
| Dec 31, 2024 | 412,000.00 |
| Sep 30, 2024 | 830,000.00 |
| Sep 30, 2024 | 830,000.00 |
| Jun 30, 2024 | 776,000.00 |
| Jun 30, 2024 | 776,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |